LUM001 and placebo in paediatric patients with Alagille Syndrome-IMAGO

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients with Alagille Syndrome.

• IRAS ID

  127960

• Contact name

  Richard Thompson

• Contact email

  richard.j.thompson@kcl.ac.uk

• Sponsor organisation

  Lumena Pharmaceuticals UK

• Eudract number

  2012-005346-38

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  13/LO/0782

• Date of REC Opinion

  10 Jun 2013

• REC opinion

  Favourable Opinion